Cyclooxygenase-2 (COX-2) is upregulated in many tumors including neuroblastoma, and its overexpression has been implicated in resistance to p53-dependent apoptosis. Although p53 is rarely mutated in neuroblastoma, the p53 protein is rendered inactive via several mechanisms including sequestration in the cytoplasm. Here, we show that COX inhibitors inhibit the growth of neuroblastoma and when combined with low doses of chemotherapy, exert synergistic effects on neuroblastoma cells. Following COX inhibitor treatment, HDM2, which targets p53 for ubiquitin-mediated degradation, is downregulated, resulting in an attenuation of p53 ubiquitination and an increase in p53 half-life. The level of HDM2 phosphorylation at ser166, which influences both HDM2 and p53 subcellular distribution, is markedly diminished in response to COX inhibitors and is associated with increased p53 nuclear localization. Combining COX inhibitors with low-dose chemotherapy potentiates apoptosis and p53 stability, nuclear localization, and activity. p53 knockdown by siRNA resulted in the rescue of COX-inhibitor-treated cells, indicating that COX inhibitor-induced apoptosis is, at least in part, p53-dependent. Taken together, these results provide the first evidence that COX inhibitors enhance chemosensitivity in neuroblastoma via downregulating HDM2 and augmenting p53 stability and nuclear accumulation.
Introduction
Cyclooxygenase (COX) inhibitors are non-steroidal anti-inflammatory drugs (NSAID), which were initially developed as analgesics and anti-inflammatory agents, but have recently been shown to have anti-cancer effects (reviewed in Gasparini et al. (2003) and Thun et al. (2002) ). COX inhibitors inhibit the COX enzyme that catalyses the rate-limiting step in the conversion of arachidonic acid to prostaglandins (PGs). While the COX-1 isoform is constitutively expressed, COX-2 is inducible by inflammatory and mitogenic stimuli and is overexpressed in many cancer cell lines as well as malignant primary tumors (Gasparini et al., 2003) . High levels of COX-2 and its product PGE 2 promote malignant transformation by inhibiting apoptosis and stimulating cell proliferation, tumor cell invasiveness and angiogenesis (reviewed in Dannenberg and Subbaramaiah (2003) ; Gasparini et al. (2003) ; Brown and DuBois (2005) ). Thus, one mechanism by which COX-2 inhibitors are thought to suppress tumorigenesis is by directly inhibiting the COX-2 enzyme and the COX-2-derived prostanoids. In addition, the selective COX-2 inhibitor (celecoxib) has been shown to induce apoptosis and cell cycle arrest in COX-2-negative cells, providing evidence of COX-2-independent mechanism(s) (Waskewich et al., 2002; Han et al., 2004) .
Neuroblastoma, a tumor of the sympathetic nervous system, is one of the most common pediatric tumors. Despite an increased understanding of the molecular and genetic events involved in neuroblastoma pathogenesis, cure rates for metastatic neuroblastoma remain very low (Brodeur, 2003) . Although p53 is mutated in over 50% of tumors, p53 mutations are rarely present in de novo neuroblastoma (Imamura et al., 1993; Komuro et al., 1993; Vogan et al., 1993; Hosoi et al., 1994) . However, wild-type p53 is inactivated in some neuroblastoma via various mechanisms including p53 cytoplasmic sequestration (Moll et al., 1995; Tweddle et al., 2001) , HDM2 amplification (Corvi et al., 1995) , inactivation of p14 ARF (Carr et al., 2006) , and overexpression of Twist (Valsesia-Wittmann et al., 2004) . Cellular levels of p53 are low under normal conditions and are tightly regulated by one of p53's own target gene products HDM2, an E3 ubiquitin ligase for p53, which in turn can be modulated by p14 ARF . In response to aberrant growth signals and cytotoxic stresses such as DNA damage, the p53 protein is stabilized and activates downstream target genes involved in apoptosis and cell cycle arrest (Vousden and Lu, 2002; Oren, 2003) .
Recent reports indicate a complex relationship between the tumor suppressor p53 and COX-2. While some studies demonstrate that wild-type p53 overexpression leads to increased COX-2 levels (Han et al., 2002; Corcoran et al., 2005) , other studies report opposite effects where p53 inhibits COX-2 transcription (Subbaramaiah et al., 1999; Liu et al., 2005) . However, there is general agreement in the literature regarding the effect of COX-2 on p53 activity. Overproduction of COX-2 inhibits p53 transcriptional activities and apoptosis (Han et al., 2002; Choi et al., 2005; Corcoran et al., 2005) , at least in part by interacting with p53. COX-2 has also been shown to affect p53 subcellular localization in colon cancer. PGA 1 and PGA 2 , downstream products of COX-2, have been shown to inhibit p53 transcriptional activity and p53 nuclear localization (Moos et al., 2000) . Furthermore, the selective COX-2 inhibitor celecoxib has been reported to increase p53 nuclear localization in colon cancer (Swamy et al., 2003) .
Neuroblastoma has been reported to express COX-2 and is sensitive to COX inhibitors both in vitro and in vivo (Johnsen et al., 2004; Parashar et al., 2005; Parashar and Shafit-Zagardo, 2006) . There have also been a small number of preclinical studies evaluating the effectiveness of combining COX-2 inhibitors with conventional chemotherapeutic agents in adult cancers (Hida et al., 2000; Trifan et al., 2002; Winters et al., 2005) . However, mechanisms by which COX inhibitors induce apoptosis and enhance chemosensitivity in neuroblastoma have not been fully elucidated. We hypothesized that COX inhibitors may increase nuclear retention of p53 in neuroblastoma resulting in increased p53-dependent apoptosis and enhanced sensitivity to other DNA damaging agents.
In this study, we demonstrate that neuroblastoma is sensitive to both selective and non-selective COX inhibitors and that both classes of COX inhibitors can sensitize neuroblastoma cell lines as well as primary tumor cells to chemotherapy-induced apoptosis. We show that COX inhibitors increase p53 nuclear localization and half-life, both of which are potentiated by combining COX inhibitors with chemotherapeutic agents. Furthermore, the increase in p53 activity is accompanied by downregulation of phospho-HDM2 and inhibition of p53 ubiquitination. Moreover, knockdown of p53 using siRNA decreases the level of apoptosis in response to COX inhibitors. Hence, our findings provide the first evidence that COX inhibitors enhance chemosensitivity in neuroblastoma and that COX inhibitors induce apoptosis via augmentation of p53 activity and nuclear retention. The results of this study suggest that using COX inhibitors or other agents aimed at modulating p53 nuclear localization may induce synergistic effects with chemotherapies in the treatment of neuroblastoma and other tumors, such as breast and colon cancers, in which p53 is predominantly sequestered in the cytoplasm.
Results

Neuroblastoma is sensitive to COX inhibitors
Both the selective COX-2 inhibitor celecoxib (CXB) and the non-selective COX inhibitors diclofenac (DFN) and indomethacin (IND) were active against neuroblastoma cells in vitro. As amplification of the MYCN oncogene is an important prognostic factor in neuroblastoma (Look et al., 1991) , we tested neuroblastoma cells with different MYCN status. COX inhibitors were able to induce dosedependent inhibition of cell growth in both MYCN amplified (IMR-5) and non-amplified (SK-N-AS, SK-N-SH, SH-SY5Y, SH-EP) neuroblastoma cell lines (Figure 1 ). SH-SY5Y and SH-EP are subclones of SK-N-SH and have been demonstrated to exhibit different characteristics including HDM2 expression levels as well as sensitivity to DNA damage (Rodriguez-Lopez et al., 2001; Tweddle et al., 2001) . The IC 50 ranged from 50 to 60 mM for CXB, 260 to 370 mM for DFN, and 160 to 440 mM for IND (Figure 1 ). Additional neuroblastoma cell lines that were tested by our group and Johnsen et al. (2004) were also found to be sensitive to COX inhibitors.
COX inhibitors enhance chemosensitivity in neuroblastoma Treatment of IMR-5 cells with each of the three COX inhibitors in combination with either low doses of doxorubicin (DOX) or etoposide (VP-16) resulted in more cell death than either treatment alone as assayed by Trypan blue (Po0.01) (Figure 2a ). In addition, combination treatment also caused more growth inhibition as measured by the MTT assay (Po0.01) ( Figure 2b ). As both COX inhibitor and chemotherapy alone could cause significant cell death, we next used the combination index (CI), as described by Talalay (1981, 1984) (Figure 2b ). As cell lines cultured for long periods may not be representative of patient tumor, we tested this combination therapy on primary neuroblastoma cells isolated from the bone marrow of a patient with refractory metastatic disease (first and second passage) and found that combination treatment also resulted in significant growth inhibition in primary neuroblastoma cells (Supplemental Figure S1 ).
COX inhibitors potentiate chemotherapy-induced apoptosis
We next asked whether the growth inhibition from combination treatment with COX inhibitor and chemotherapy was due to enhanced apoptosis. As shown in Figure 3a , CXB alone caused only minimal apoptosis; however, combining CXB with chemotherapy led to significant increase in apoptosis as detected by flow cytometry. The sub-G 1 fraction increased by an additional 33 and 18% when CXB was combined with DOX and VP, respectively (Po0.0001). Chemotherapy-induced apoptosis was also enhanced with the addition of the nonselective COX inhibitors DFN and IND (Po0.0001) (Figure 3b ). Induction of apoptosis was confirmed by immunoblot analysis of cleaved-PARP (apoptosis marker). Synergistic combinations of COX inhibitors with chemotherapy resulted in increased levels of cleaved-PARP when compared to either treatment alone ( Figure 3c ).
COX inhibitors induce p53 and prolong p53 half-life in neuroblastoma
We next investigated the mechanisms by which COX inhibitors induce cell death in neuroblastoma. As COX-2 has been reported to interfere with p53-mediated pathways and p53-induced apoptosis during cellular stress and DNA damage (Han et al., 2002; Corcoran et al., 2005), we examined whether the cytotoxic effects of COX inhibitors were associated with p53 induction. We found that DFN increased p53 levels in IMR-5 cells in a dose-dependent manner ( Figure 4a ). Similar increases in p53 following treatment with COX inhibitors were also observed in SK-N-SH cells (Supplemental Figure S2) . Furthermore, the potentiation of apoptosis by combination treatment was associated with higher levels of both p53 and the p53 target, p21
, than either treatment alone (Figure 4b ), suggesting that enhancement of p53 induction resulted in increased p53 transcriptional activity. We next asked whether increased p53 level was associated with stabilization of p53. As demonstrated by cycloheximide (CHX) assay, p53 half-life was significantly prolonged from 6 min in untreated cells to 33 min in DFN-treated cells and to 87 min when DFN was combined with DOX ( Figure 4c and d).
Augmentation of p53 nuclear localization by COX inhibitors Swamy et al. (2003) previously reported that p53 nuclear localization is increased in colon cancer cells treated with CXB. As p53 cytoplasmic sequestration is commonly observed in neuroblastoma, we asked whether the increased p53 activity observed with COX inhibitors was associated with p53 nuclear accumulation in neuroblastoma. Immunofluorescence studies demonstrated that all three COX inhibitors significantly increased p53 nuclear localization in SK-N-SH. The percentage of cells with p53 nuclear signal increased from 10% in controls to between 50 and 70% in COX inhibitortreated cells. Furthermore, p53 nuclear localization increased by an additional 20% when CXB or IND was combined with DOX ( Figure 5a ). Synergistic combinations of COX inhibitors and chemotherapy also resulted in more pronounced p53 nuclear localization in both SK-N-SH and IMR-5 cells (Figure 5b ).
In addition, COX inhibitor-induced p53 nuclear localization was confirmed using subcellular fractionation. Figure 5c illustrates that the majority of p53 is detected in the cytoplasmic fraction of untreated IMR-5 cells and nuclear p53 increased after exposure to DFN. Densitometry was used to quantify the changes in p53 in both nuclear and cytoplasmic compartments. While cytoplasmic p53 only increased by 1.9-fold after 24 h DFN treatment, nuclear p53 increased by 4.7-fold. To demonstrate p53 nuclear localization as an initiating event, we treated cells with DFN alone and in combination with DOX or VP for 6 h. We found that COX inhibitor-induced p53 nuclear localization occurred as early as 6 h and there were significant synergistic effects on p53 nuclear localization when DFN was combined with chemotherapy ( Figure 5d ). While low-dose DOX or VP had minimal effect on p53 nuclear localization, nuclear p53 increased by 10.6-and 13.3-fold when DOX or VP was combined with DFN, respectively ( Figure 5e ). In comparison, cytoplasmic p53 only increased marginally in all treatments at 6 h.
COX inhibitors downregulate HDM2 and inhibit HDM2 phosphorylation
To examine the molecular mechanisms underlying the observed COX inhibitor induced nuclear localization of p53, we investigated the role of PARC and HDM2. PARC (p53-associated parkin-like cytoplasmic protein) is a Parkin-like ubiquitin ligase that has been shown to anchor p53 to the cytoplasm in neuroblastoma (Nikolaev et al., 2003) . We found that PARC levels were unaffected by COX inhibitors or combination treatment (Supplemental Figure S3 ). In contrast, the levels of the E3 ligase HDM2, a critical regulator of p53 stability and subcellular localization (Brooks and Gu, 2004) , were decreased at early time points following treatment with COX inhibitors (Figure 6a ). Phosphorylation of HDM2 at serine residue 166 has previously been reported to enhance HDM2 translocation to the nucleus, where it binds to p53 and affects both p53 stability and localization (Roth et al., 1998; Mayo and Donner, 2001) . Hence, we asked whether HDM2 phosphorylation could be affected by treatment with COX inhibitors. We found that both CXB and DFN inhibited phosphorylation of HDM2 (ser166) as early as 2 h after treatment ( Figure 6b ) with a sustained effect up to 48 h (Figure 6c ). In addition, synergistic combinations of COX inhibitors and chemotherapy also resulted in downregulation of both HDM2 and phosphorylated-HDM2 ( Figure 6d ).
As HDM2 mediates both p53 nuclear export and degradation, we next asked whether COX inhibitors affect p53 stability and nuclear localization through inhibition of HDM2-mediated p53 ubiquitination. As ubiquitinated-p53 is rapidly degraded by the proteasome system, the proteasome inhibitor MG132 was added to facilitate detection of ubiquitinated-p53. As shown in Figure 6e , a ladder with modified p53 bands was easily detected in control cells treated with MG132. The p53 ladder is consistent with endogenous ubiquitinated-p53, similar to that demonstrated by others (Wang et al., 2002; Isaacs et al., 2001) in neuroblastoma cells. In contrast, the p53 ladder was barely detectable in COX inhibitor-treated cells. Furthermore, we found that COX inhibitors induced a dose-dependent inhibition of p53 ubiquitination (Supplemental Figure S4) . These results suggest that HDM2-mediated ubiquitination of p53 is inhibited by COX inhibitors.
COX inhibitor-mediated apoptosis is p53 dependent Our data demonstrates that p53 levels and nuclear localization increase upon treatment with COX inhibitors alone and in combination with chemotherapy. To determine whether COX inhibitor-mediated apoptosis is p53-dependent, we performed p53 siRNA to knock down p53 expression. p53 knock down resulted in rescue of CXB-treated cells with diminished expression of the apoptosis marker, cleaved-PARP (Figure 7a ), suggesting that COX inhibitor-mediated apoptosis is, at least in part, due to p53 activity. Moreover, reduction in apoptosis and p21 waf1/cip1 levels were also observed following p53-knockdown in cells exposed to COX inhibitor/DOX combination treatment (Figure 7a and  b) . Thus, our data demonstrate that COX inhibitors induce apoptosis in neuroblastoma and enhance waf1/cip1 and p53 (DO-1) immunoblots of IMR-5 cells treated for 48 h with the following drugs: DFN 100 mM, IND 200 mM, DOX 3 ng/ml, VP 0.1 mM. (c) IMR-5 cells were exposed to the following drugs for 24 h: DFN 100 mM, DOX 3 ng/ml, DFN 100 mM/DOX 3 ng/ml. Cells were then harvested after exposure to cycloheximide (CHX) for the indicated times and immunoblotted with p53 (DO-1) antibody. (d) Levels of p53 were quantified by densitometry and optical density was plotted on a semi-log scale to derive the half-life (T1/2) of p53. Vinculin was used as loading control.
chemosensitivity by augmentation of p53 activity and nuclear localization via downregulation of HDM2.
Discussion
Numerous epidemiological and experimental studies have provided evidence to support the use of NSAIDs or COX inhibitors in anticancer therapy (Thun et al., 2002; Dannenberg and Subbaramaiah, 2003; Gasparini et al., 2003; Brown and DuBois, 2005) . In addition, a small number of studies have suggested synergistic effects when COX inhibitors are combined with chemotherapy (Hida et al., 2000; Trifan et al., 2002; Winters et al., 2005) . COX-2 has been shown to promote tumorigenesis and overexpression of COX-2 has been reported in numerous adult cancers, and more recently in neuroblastoma cell lines and primary tumors (Johnsen et al., 2004) . In this study, we demonstrate that neuroblastoma cell lines are sensitive to both selective COX-2 and non-selective COX inhibitors. We also provide the first evidence that COX inhibitors in combination with low doses of chemotherapy commonly used in neuroblastoma treatment (doxorubicin and etoposide) have synergistic effects on both growth inhibition and apoptosis. Furthermore, we demonstrate that such combinations are effective in reducing growth of primary neuroblastoma cells isolated from the bone marrow of a patient with refractory disease. Our findings demonstrate that p53 upregulation is involved in sensitizing neuroblastoma cells to COX inhibitors and chemotherapy. Thus far, no studies have addressed the role of COX inhibitors and p53 in neuroblastoma or other cell types in which p53 is primarily localized in the cytoplasm.
Following treatment with DNA damaging agents such as chemotherapies, p53 is stabilized by activation of multiple pathways, most notably the p53-HDM2 feedback loop (Harris and Levine, 2005) . The E3 ligase HDM2 plays a critical role in modulating p53 activity at multiple levels. The E3 ligase activity results in ubiquitin-mediated degradation of p53, while the binding of HDM2 to p53 affects p53 nuclear export. p53 is also stabilized at the protein level as a result of posttranslational modifications, such as site-specific phosphorylation and acetylation. These modifications can affect both the interaction between HDM2 and p53, as well as the nuclear export signals (NES) (Stommel et al., 1999; Inoue et al., 2005) . In certain tumors, including neuroblastoma, p53 cytoplasmic sequestration represents one of the mechanisms by which p53 is inactivated. However, high doses of chemotherapies can 'relocalize' p53 to the nucleus (Isaacs et al., 2001; Cui et al., 2002) . Hence drugs that lead to enhanced p53 nuclear localization may lead to enhanced apoptosis by increasing activated nuclear p53 to mediate the response to chemotherapies.
In this study, we show that both classes of COX inhibitors promote nuclear localization of p53 in neuroblastoma. Furthermore, the nuclear accumulation of p53 following COX inhibitor treatment was enhanced by the addition of low-dose doxorubicin or VP-16, which as single agents at the doses used in our experiments induce minimal nuclear p53. Notably, most studies demonstrating chemotherapy-induced p53 nuclear localization in neuroblastoma use very high doses of chemotherapy, such as doxorubicin doses of approximately 100-fold higher than the doses used in our experiments (Isaacs et al., 2001; Cui et al., 2002) . The increase in nuclear p53 observed in this study may be due to the dissociation of the interaction between p53 and cytoplasmic anchoring proteins or to the inhibition of p53 nuclear export. PARC, an E3 ligase that anchors p53 to the cytoplasm has been shown to be highly expressed in neuroblastoma and siRNA knock down of PARC in neuroblastoma leads to enhanced p53 nuclear retention and increased apoptosis in neuroblastoma cells treated by chemotherapy (Nikolaev et al., 2003) . However, in our study, following treatment with COX inhibitors, in the absence and presence of chemotherapy, PARC levels were not affected. In contrast, HDM2 levels were diminished following treatment with COX inhibitors. Specifically, we found that both COX inhibitors alone and in combination with chemotherapy decrease the levels of P-HDM2 (ser166), which correlates with the early increase in p53 nuclear localization. Previous studies demonstrate that nuclear accumulation following stress such as DNA damage involves the inhibition of HDM2-dependent nuclear export of p53 (Ashcroft et al., 2002; Oren, 2003; Inoue et al., 2005) . Furthermore, inhibition of HDM2 by antisense oligonucleotides resulted in accumulation of nuclear p53 in neuroblastoma, as well as other tumors with p53 cytoplasmic sequestration (Lu et al., 2000) . In addition, phosphorylation of HDM2 at ser166 has been shown to promote HDM2 nuclear localization (Mayo and Donner, 2001; Ashcroft et al., 2002) . Thus, the downregulation of HDM2 and P-HDM2 seen in this study is consistent with a role for COX inhibitors in blocking p53 nuclear export in a manner similar to that induced by some DNA damaging agents. In addition to the changes in subcellular localization of p53 seen with COX inhibitors, we also detected a dose-dependent increase in the total level of p53 protein. This increase was further enhanced in the presence of low-dose chemotherapy and was associated with an increase in transcriptional activation of the p53 downstream target gene p21 waf1/cip1 . Moreover the abrogation of p53 by siRNA significantly reduced apoptosis and p21 waf1/cip1 expression induced by these drug combinations. This increase in p53 was likely due to protein stabilization, based on our observed decrease in p53 laddering consistent with ubiquitination and prolongation of p53 half-life. Increased stability of p53 can be due to decreased levels and/or activity of HDM2. Given the downregulation of HDM2 detected in our studies, it is likely that a reduction in E3-ligase activity of HDM2 levels results in impaired ubiquitination and proteasomal degradation of p53. A similar mechanism has been implicated for the nitric oxide analogue GNSO. Oren and co-workers reported that GNSO promoted p53 nuclear retention in neuroblastoma in the setting of a similar downregulation of HDM2, subsequent rise in p53 levels, and a concomitant decrease in ubiquitination of p53 (Wang et al., 2002 (Wang et al., , 2003 .
Phosphorylation of N-terminal p53 residues at ser15 and 20 have also been reported to increase p53 stability, nuclear localization, and transcriptional activity by affecting the interaction between HDM2 and p53 as well as altering the NES (Stommel et al., 1999; Zhang and Xiong, 2001) . Different DNA damaging agents induce varying degrees of p53 phosphorylation in various cell types, including neuroblastoma (Isaacs et al., 2001; Ashcroft et al., 2002; Wang et al., 2003) . In our study, we found phosphorylation of p53 serine residue 15 following treatment with COX inhibitors (data not shown). Hence it is likely that following COX inhibitor treatment, phosphorylation of p53 also contributes to the observed stabilization and nuclear localization of p53. Another possible mechanism by which COX-2 has been reported to modulate p53 is by direct binding (Choi et al., 2005; Corcoran et al., 2005) , suggesting that COX inhibitors might interfere with this interaction. We only detected COX-2 binding to p53 in neuroblastoma cells with very high levels of COX-2 protein; and COX inhibitor treatment did not affect this binding (Supplemental Figure S5) . Interestingly, it has been reported that overexpression of the COX-2 protein does not affect the level of endogenous p53 (Corcoran et al., 2005) . Thus, in neuroblastoma cells, the binding of the COX-2 protein to p53 is not affected by treatment with COX inhibitors or chemotherapy and is unlikely to mediate the effects that we have observed. Instead, the p53 stabilization effect that we report is associated with changes in HDM2 phosphorylation, and may be COX-2 independent.
Our data implicates HDM2 in COX inhibitormediated apoptosis, as well as the enhanced sensitivity to chemotherapy in neuroblastoma. Only one study has previously demonstrated a connection between COX-2 Figure 7 p53 siRNA inhibits p21 waf1/cip1 expression and PARP cleavage induced by COX inhibitor treatment. (a) IMR-5 cells were transfected with siRNA oligonucleotides directed against p53 (p53-1) (lanes 3, 6, 9, 12). As siRNA controls, cells were either transfected with scrambled E2F1 siRNA (control ¼ CNTRL) (lanes 2, 5, 8, 11) or no siRNA/Oligofectamine (untransfected ¼ UNTFX) (lanes 1, 4, 7, 10). At 24 h after transfection, cells were treated for 48 h with the following drug combinations: CXB 50 mM (lanes 4-6), CXB 50 mM/DOX 3 ng/ml (lanes 7-9) and DFN 100 mM/DOX 3 ng/ml (lane 10-12). Controls (lanes 1-3) received no drugs. Cells were then immunoblotted with cleaved-PARP and p53 (DO-1) antibodies. It should be noted that transfection with siRNA and oligofectamine reagents (lane 2) resulted in a modest increase in p53, as compared with untransfected cells (lane 1).
waf1/cip1 and p53 immunoblot of IMR-5 cells transfected as in (a) and with a second p53 siRNA (p53-2) and subsequently treated for 48 h with DFN 100 mM/DOX 3 ng/ml (lane 4-6). Controls (lane 1-3) received no drugs. Vinculin was used as loading control. and HDM2. Liu et al. (2005) demonstrate that, in response to hypoxia, overexpression of the COX-2 protein leads to decreased apoptosis and increased levels of phospho-HDM2 in a prostate carcinoma cell line. However, the mechanisms by which COX-2 modulates HDM2 and COX inhibitors downregulate HDM2 is still not clear. In the hypoxia experiments, Liu et al. (2005) suggest that hypoxia-inducible factor alpha (HIF1a) is affecting both HDM2 and COX-2. However, another plausible mechanism that may explain our findings is the downregulation of Akt/PDK1. Mitogeninduced activation of PI3-kinase and its downstream target Akt results in phosphorylation of HDM2 on ser166 and 168 and enhanced HDM2 nuclear localization (Mayo and Donner, 2001; Ashcroft et al., 2002) . Interestingly, a number of studies have demonstrated that COX-2 inhibitors induce apoptosis by blocking Akt activation in adult carcinomas (Hsu et al., 2000; Arico et al., 2002) . However, in this study, we did not observe any early changes in Akt or Akt phosphorylation that could have explained the downregulation of phosphorylated HDM2 mediated by COX inhibitors as early as 2 h. In contrast, we observed dose-dependent reduction of Akt levels after 24 h of COX inhibitor treatment (data not shown) and these late effects may account for the observed sustained downregulation of P-HDM2 up to 48 h by COX inhibitors in neuroblastoma. We also studied the effects of COX inhibitors on PTEN, a tumor suppressor known to inhibit the PI3-K/Akt pathway as well as on MAPKAPK kinase 2, a kinase that has been shown to phosphorylate HDM2 serine 166 (Weber et al., 2005) and did not observe any early changes in PTEN or MAPKAP kinase 2 (data not shown). Hence the mechanisms by which COX inhibitors regulate HDM2 levels or HDM2 phosphorylation do not involve the known HDM2 kinases for serine 166 and remain to be elucidated.
In conclusion, we provide the first evidence for synergism when COX inhibitors are combined with low doses of commonly used chemotherapeutic agents in the treatment of neuroblastoma cell lines and primary cells. Synergism occurs in the setting of increased p53 stability, p53 nuclear localization and apoptosis. Our data suggests that these COX inhibitor-mediated p53 effects are a consequence of modulation of the HDM2-ubiquitin-proteasome pathway. Small molecule inhibitors or other agents that interfere with p53-HDM2 have been shown to induce apoptosis as well as sensitize cells to chemotherapy (Fischer and Lane, 2004; Bianco et al., 2005) . Taken together the results of our study suggest that COX inhibitors in combination with chemotherapy may be synergistic in the treatment of neuroblastoma, as well as other tumors with p53 cytoplasmic sequestration through modulation of the p53/HDM2 pathway.
Materials and methods
Chemicals
Celecoxib (Pfizer Corporation, Skokie, IL, USA) was solubilized in dimethylsulfoxide (DMSO) to a final stock concentration of 100 mM. Diclofenac, indomethacin (Cayman Chemicals, Ann Arbor, MI, USA), doxorubicin, and etoposide (VP-16) (Sigma Chemical, St Louis, MO, USA), were dissolved according to manufacturers' instructions. Drugs were diluted in culture medium containing 10% fetal bovine serum (FBS) to the desired concentrations before introduction to cell cultures. Controls with similar DMSO concentration were used for comparison.
Cell culture IMR-5, SK-N-AS and SH-EP neuroblastoma cells were grown in DMEM, SK-N-SH grown in MEM and SH-SY5Y in MEM/F12 (1:1), supplemented with 10% FBS, 100 IU/ml penicillin and 100 mg/ml streptomycin, 0.1 mM non-essential amino-acid (except for SH-EP), and 1 mM sodium pyruvate (except for SH-EP and SK-N-AS). IMR-5 cells are MYCN amplified and SK-N-SH, SH-SY5Y, SH-EP and SK-N-AS are MYCN non-amplified.
Cell viability assays
Cell proliferation was measured using either the alamarBlue assay (Biosource International, Camarillo, CA, USA) or the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) colorimetric assay (Roche Applied Science, Canada) according to manufacturers' instructions. The alamarBlue assay incorporates a fluorometric/colorimetric growth indicator where changes correlate with the number of metabolically active cells. For Trypan blue exclusion test, adherent cells were trypsinized and collected with culture medium containing nonadherent cells. Trypan blue (0.4%) (Sigma) was then added to the cell suspension (1:1) and both non-viable (blue) and viable (clear) cells were counted using a hemacytometer.
Determination of synergism and antagonism Drug combination effects were measured using the combination index (CI) equation based on the multiple drug effect equation of Chou-Talalay derived from enzyme kinetic models Talalay, 1981, 1984) . The statistical method takes into account both the potency and the shape of the dose-effect curve. The CI equation for mutually exclusive drugs is given as:
where (D) 1 and (D) 2 in the numerators are the doses of drug 1 and drug 2 in combination that inhibit x% and (D x ) 1 and (D x ) 2 in the denominators are the doses of drug 1 and drug 2 alone that give x% inhibition. CI ¼ 1 indicates additive effect while CIo1 and CI>1 indicate synergism and antagonism, respectively. Mutual exclusivity is assumed for simplicity. The CI was calculated using the CalcuSyn software (Biosoft, MO, USA).
Flow cytometry
Cells (adherent and floating) were pelleted and washed with PBS. Cells were then resuspended in 70% cold ethanol and fixed overnight at 41C. Fixed cells were incubated with propidium iodide (PI) (69 mM PI in 38 mM Na citrate) containing RNase (2 ml/ml) at 371C for 20 min and at room temperature for 15 min. The PI-stained cells were analyzed for DNA content by flow cytometry. Cell cycle profile (cell number vs DNA content) was formulated using the BD (Becton, Dickinson and Company) CellQuest software program. The sub-G 1 fraction represents the apoptotic cells with hypodiploid DNA content.
Immunoblot analysis
Whole cell extracts were prepared using EBC buffer (50 mM Tris (pH 8.0), 120 mM NaCl, 0.5% nonidet P-40) supplemented with aprotonin (11.5 mg/ml), leupeptin (10 mg/ml), phenylmethylsulfonyl fluoride (50 mg/ml) and sodium orthovanadate (0.2 mM). , cleaved-PARP, phospho-HDM2 (ser166), Akt (Cell Signaling Technology, Beverly, MA, USA), HDM2 (SMP14) (Santa Cruz), vinculin (Upstate, Lake Placid, NY, USA), and horseradish peroxidase-conjugated secondary antibodies (Pierce Biotechnology, Rockford, IL, USA). Detection was performed using an enhanced chemiluminescence system (Super Signal West Pico, Pierce).
p53 half-life and ubiquitination determination At the end of the indicated drug treatments, cycloheximide (CHX) (10 mg/ml) (Sigma) was added to the cells for the indicated duration and harvested for immunoblotting. Densitometry measurement of the p53 signal was determined using the ImageJ software available from the National Institute of Health (http://rsb.info.nih.gov/ij). The quantified values, expressed as optical density, were graphed on a semi-log scale as a trendline and the half-life of p53 was derived from the trendline equation. To assess p53 ubiquitination, cells were first treated with the indicated drugs and the proteasome inhibitor MG132 (20 mM) (Boston Biochem) was added 6 h before cells were harvested to inhibit proteasome-mediated degradation of ubiquitinated-p53.
Immunofluorescence
Cells were cultured on lysine-coated cover slips in six-well plates and treated with the specified drug(s) for the indicated duration. Cells were fixed with 4% paraformaldehyde at 41C for 20 min, permeabilized with 0.2% Triton X-100 in PBS for 5 min and blocked in 2% goat serum in 0.1% Triton X-100 in PBS for 5 min. Cells were then incubated with primary antibody pAb1801 (1:1000) (p53 monoclonal mouse, Calbiochem) at room temperature for 1 h, followed by secondary antibody Cy3-conjugated goat-anti-mouse (1:200) (Jackson ImmunoResearch, West Grove, PA, USA) for 20 min. Cells were also stained with DAPI for 5 min. A Leica DMRA2 microscope was used to visualize cells. The nuclear and cytoplasmic fraction of p53 was evaluated in X100 cells.
Subcellular fractionation of p53
Cells were trypsinized and pelleted by centrifugation at 1100 r.p.m. at 41C for 5 min. Cells were resuspended by gentle inversions in lysis buffer A containing 10 mM HEPES (pH 7.9), 10 mM KCl, 1.5 mM MgCl 2 , 0.34 M sucrose, 10% glycerol, 1 mM DTT, 0.1% Triton X-100 and protease inhibitors (as used in whole cell extract) and incubated on ice for 7 min. After centrifugation at 4000 r.p.m. at 41C for 5 min, the cytoplasmic fraction was decanted and the nuclear pellet was washed with buffer A without Triton X-100. The nuclear pellet was resuspended in lysis buffer B containing 0.2 mM EGTA (pH 8), 3 mM EDTA (pH 8), 1 mM DTT) and incubated on ice for 30 min with intermittent vigorous vortexing. The nuclear fraction was collected following centrifugation at 4000 r.p.m. for 5 min at 41C. Equal amount of protein, measured using Bradford reagent, were resolved by SDS-PAGE and probed with antibodies against p53 (DO-1), vinculin, and HnRNP (Abcam). Densitometry measurement of the p53 signal was determined using the ImageJ software. All short-interfering RNA (siRNA) sequences were subjected to BLAST search to confirm the absence of homology to any additional known coding sequences in the human genome. Oligonucleotides were resuspended according to the manufacturer's instructions (Dharmacon). Cells were seeded in P-60 plates and transfected with siRNA at approximately 30-40% confluency using Oligofectamine (Invitrogen) according to the manufacturer's instructions. E2F1-scrambled siRNA transfection was used as control. The final concentration of siRNA was 75 nM. Untransfected samples did not have oligonucleotides or Oligofectamine reagent added. Cells were allowed to recover for 24 h before treatment with the indicated drugs.
